|Bid||71.20 x 1400|
|Ask||71.85 x 900|
|Day's range||70.45 - 71.76|
|52-week range||56.56 - 73.34|
|Beta (5Y monthly)||0.41|
|PE ratio (TTM)||17.53|
|Earnings date||26 Oct 2021 - 01 Nov 2021|
|Forward dividend & yield||2.84 (3.97%)|
|Ex-dividend date||14 Sep 2021|
|1y target est||75.99|
Yahoo Finance’s Anjalee Khemlani reports the FDA advisory panels' second vote regarding Covid-19 boosters.
Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.
FOSTER CITY, Calif., September 16, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the Phase 3 ASCENT study evaluating Trodelvy® (sacituzumab govitecan-hziy) in patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies, at least one of them for metastatic disease. In a retrospective subgroup analysis, Trodelvy improved progression-free survival (PFS), overall survival (OS) and objective response